FOXP3 and cancer: Immune histology of residual RT2-cancers showed CD3+ cells, MHC class II+ and F4/80+ cells following ICB/AT treatment but only very few or no Foxp3+ regulatory T cells, CD8+ or CD49b+ cells (Fig. 5a, Supplementary Fig. 8a–c).